TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/28/2025
Back to search
Official data from USPTO
T-CEPTOR
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
T-CEPTOR
ST13
US500000098081098Class
5, 42, 44
Filing
98081098
Registration
7683956
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
05/03/2025
Trademark type
Word
Nice classes
5, 42, 44
Filing date
07/12/2023
Registration date
02/11/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/11/2025
Last transaction
05/03/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
Cambridge, GB
Examiner
ANDERSON, DANIELLE
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
T-Therapeutics Limited
Representatives
Stacy J. Grossman SGIP
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; chemical and biological pharmaceutical preparations for medical purposesfor protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; chemical preparations for use in DNA analysis for medical purposes; DNA synthesis inhibitors for medical purposespharmaceutical preparations for protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; biological preparations for the treatment of cancer; biological preparations for the treatment of viral and bacterial infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use for the treatment of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; immunotherapeutic drugs namelypharmaceutical preparations for protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; reagents for medical use; diagnostic preparations for medical use; diagnostic reagents for medical use; preparations for detecting genetic predispositions for medical purposes
Class 42
Scientific and technological servicesscientific research and development in the field of pharmaceuticals for genome engineering and biopharmaceutical drug development for protection from infectionscancerdisease or inflammation; technical research in the field of pharmaceutical studies; industrial analysis and industrial research services in the field of pharmaceuticals and genome engineering; research in the field of DNA repair technology; design and development of computer hardware and software; genetic microbiology and microbiome research for scientific research purposes; scientific research in the field of genetics and genetic engineering; clinical research in the field of pharmaceuticalsbiopharmaceutical drug development and genome engineering for protection and prevention from infectionscancerdisease or inflammation; scientific research in the nature of conducting clinical trials for others; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibiotics; research and development of microorganisms and cells in the nature of guided nuclease-based biocides; scientific research in the nature of conducting clinical trials for pharmaceutical products for others; bacteriological research; scientific research for medical purposes in the field of viruses and viral diseases; biological research; scientific screening and assaying being drug screening for scientific research purposes; chemical analysis; chemical research; DNA screening for scientific research purposes; genetic testing of laboratory animals for research purposes; biochemical engineering services being biochemical research and development; providing medical and scientific research information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific research information in the field of pharmaceuticals and scientific research consulting in the field of pharmaceuticals
Class 44
Medical services; diagnostic and prognostic medical services; veterinary services; medical analysis services relating to the treatment of persons; pharmaceutical advice; medical and health care services relating to DNAgeneticsgenetic pathogen testing for diagnostic or treatment purposes; medical screening and assaying in the nature of medical laboratory analysis services relating to the treatment of persons; DNA screening for medical purposes
Publications
History of USPTO decisions and trademark events.
39 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/28/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/28/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/28/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/28/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/11/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
02/11/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/24/2024
PUBO
PUBLISHED FOR OPPOSITION
12/24/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/18/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/26/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
11/22/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/22/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
11/22/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/22/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/13/2024
GNFR
FINAL REFUSAL E-MAILED
11/13/2024
CNFR
FINAL REFUSAL WRITTEN
11/13/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/09/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/09/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/10/2024
GNRT
NON-FINAL ACTION E-MAILED
07/10/2024
CNRT
NON-FINAL ACTION WRITTEN
07/10/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/11/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/11/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/31/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/31/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/31/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/27/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/27/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/27/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/23/2024
GNRT
NON-FINAL ACTION E-MAILED
03/23/2024
CNRT
NON-FINAL ACTION WRITTEN
03/23/2024
DOCK
ASSIGNED TO EXAMINER
03/20/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/10/2023
NWAP
NEW APPLICATION ENTERED
07/15/2023
Continuous trademark protection
Get notified about every new filing that threatens T-CEPTOR or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.